

## WHC Received 1 January 2022 - 31 August 2022

| WHC Ref      | WHC Title   | Status             | Applicable to PHW? | Date Issued   | Deadline for Action /Response | Lead Exec  | Compliance Statement  | Process Complete? |
|--------------|---|--------------------|--------------------|---------------|-------------------------------|--|---|-------------------|
| WHC/2022/008 | New Records Management Code of Practice for Health and Care 2022  | Action             | Yes                | 29 July 2022  | Expires / Review May 2023     | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | 28/9/22: This is in progress currently being reviewed by the Information Governance Team to review the requirements to ensure our compliance with the WHC. This will be done in conjunction with the Phase 2 of the records management project which commenced the week of 26 September. This WHC remains open.   | In Progress       |
| WHC/2022/010 | Amendments to Model Standing Orders, Reservation and Delegation of Powers and Model Standing Financial Instructions – NHS Wales | Action             | Yes                | 29 March 2022 | Not applicable                | Helen Bushell, Board Secretary and Head of Board Business Unit                                       | The WHC has been enacted. The Organisations Standing Orders, Reservation and Delegation of Powers and Standing Financial Instructions (which form part of the Standing Orders) were amended and then approved by the Board on the 27 May 2021.  | Yes               |
| WHC/2022/002 | NHS Wales National Clinical Audit and Outcome Review Plan Annual Rolling Programme for 2022/23                                  | Information/Action | Yes                | 01 June 2022  | N/A                           | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | The Clinical Audit Team have confirmed that this WHC has been reviewed and is not relevant for PHW in 2022-23. The only audit included in the National clinical audit and outcome review plan that is relevant to PHW is the All Wales Audiology Audit. However, Newborn Hearing Screening is only required to submit data for this every two years, which they did in 2021-22 and will again in 2023-24.   | Yes               |
| WHC/2022/005 | Welsh Value in Health Centre – data requirements  | Action             | Yes                | 24 March 2022 | Immediate                     | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | The WHC has been enacted. Relevant action has been incorporated in to the planning for the 2022/23 Flu Vaccine Programme, which is reported to our Quality, Safety and Improvement committee for assurance.   | Yes               |
| WHC/2022/013 | 2022/23 LHB, SHA & Trust Monthly Financial Monitoring Return Guidance   | Compliance         | Yes                | 26 April 2022 | Expires/Review April 2023     | Huw George, Deputy Chief Executive, Executive Director Operations and Finance                        | This WHC has been enacted, and we are complying with the guidance and requirements within the WHC for monthly financial monitoring returns for 2022/23  | Yes               |
| WHC/2022/014 | AMR & HCAI IMPROVEMENT GOALS FOR 2021-23  | Action/Information | Yes                | 01 March 2022 | Expires/Review 31 March 2023  | Meng Khaw, National Director of Health Protection and Screening Services, Executive Medical Director | <p>This WHC was first issued in September 2021, with an extension of the Improvement Goals to End March 2023 subsequently confirmed. A compliance form was previously submitted on 7th February 2022 – see attached.</p> <p>WHC (2021) Number 028 initially set out the actions required by the Health service across Wales to deliver on improvement goals set to address the UK Antimicrobial Resistance Strategy, WHC (2022) Number 014 extended the term of the improvement goals to end March 2023. PHW (HARP Programme team) role is to deliver the surveillance of Healthcare associated Infections, antimicrobial resistance and usage and through this we provide the underpinning monitoring data against which the improvement goals are set. PHW also provides expert IP&amp;C advice and Antimicrobial Stewardship / prescribing advice to assist NHS Wales and partners with their delivery of the improvement goals. Public Health Wales has continued to deliver these surveillance programmes and advice throughout the pandemic although services have been constrained somewhat by the COVID response.</p> <p>This WHC has been enacted. The HARP Programme work-plan has incorporated all the requirements to support the NHS in Wales to deliver on these improvement goals, as well as ensuring that the AMR Steering Board (chaired by DCMO Wales Prof. Chris Jones) and the supporting HCAI Delivery Board and AMR Delivery Board and enabled and supported with expert advice from the HARP Programme team.</p> <p>The HARP Programme has a suite of surveillance in place to underpin the UK AMR Strategy milestones and a reporting system by which HBS and Trusts are informed of their position in relation to antimicrobial usage, antimicrobial resistance, HCA-Infections. The HARP Programme also delivers education and best practice sharing opportunities through its programme of Antimicrobial Stewardship and Infection Prevention and Control Forums, which have been re-established post COVID with Summer forums held for both.</p> | Yes               |
| WHC/2022/015 | Changes to the vaccine for the HPV immunisation programme   | Action             | Yes                | 25 May 2022   | None specified                | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | This WHC has been enacted. The Vaccine Preventable Disease Programme have been working alongside Welsh Government, UKHSA and the Local Health Boards to prepare for the change from Gardasil to Gardasil 9 for some time. This has been enacted through amendments to public information, consent forms and training provided to partners by VPDP. The completion of the transition from Gardasil to Gardasil-9 was confirmed on 28th June 2022 and this is now the only product available to order by health boards. Therefore this transition programme has been successfully concluded.  | Yes               |
| WHC/2022/016 | The National Influenza Immunisation Programme 2022-23   | Action             | Yes                | 01 June 2022  | None specified                | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | Public Health Wales have commenced the planning and implementation of the internal staff Influenza Immunisation Programme in line with WHC (2022) 010. The Internal Influenza Vaccination Delivery Plan 2022-23 was provided to QSIC 16 August 2022 and the committee was asked to consider and take assurance from the plan. Our aim is to maximise the staff uptake of immunisations for the 2022-23 campaign in line with WHC (2022) 016 objectives to increase coverage in all eligible groups.   | Yes               |

|              |  |                                       |     |                |                    |  |   |            |
|--------------|--|---------------------------------------|-----|----------------|--------------------|--|---|------------|
| WHC/2022/018 | Guidelines for managing patients on the suspected cancer pathway | Compliance                            | Yes | 30 June 2022   | N/A                | Meng Khaw, National Director of Health Protection and Screening Services, Executive Medical Director | These guideline are relevant to the Breast Screening Programme, Bowel Screening Programme and Cervical Screening Programme. The pathways for Breast, Colorectal and Cervical all include screening programmes as one of the routes into the pathway. This Welsh Health Circular has been shared with Heads of Programme for these programmes and also received at the Screening Division Senior Management Team on 9 August 2022. The screening programmes points of suspicion for the pathway is complied with as it is from the point of the outcome of the screening test.<br>The timescales in the pathways are not currently being met due to the recovery from the covid pandemic across screening and the healthcare system. | Yes        |
| WHC/2022/020 | Never Events – Policy and Incident List July 2022                | Compliance/<br>Action/<br>Information | Yes | 22 July 2022   | Immediate          | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | A review of our compliance against the points covered within this WHC has taken place to ensure compliance.   | Yes        |
| WHC/2022/021 | National Optimal Pathways for Cancer (2022 update)               | Action                                | Yes | 28 July 2022   | 30 September 2022  | Meng Khaw, National Director of Health Protection and Screening Services, Executive Medical Director | The WHC has been enacted. The WHC applies to the three cancer screening programmes at PHW (cervical, bowel and breast). The Screening Division has confirmed compliance with working in line with the pathways outlined within the WHC.   | Yes        |
| WHC/2022/022 | The Role of the Community Dental Service                         | Action                                | Yes | 22 August 2022 | Review August 2024 | Angela Jones, Acting Director of Health and Well-Being   | The WHC applies to the Community Dental Service employed by Health Boards. This workforce supports aspects of the PH programmes under the leadership of Public Health Wales, so has an indirect impact to the delivery of D2S, Gwen am Byth and the Dental Survey. This is being monitored. The Dental Public Health teams stand ready to support Health Boards in their role.<br><br>The is a Dental Inquiry being led by the Welsh Government Health and Social Care Committee in October 2022 where the capacity of the CDS will be further investigated. Public Health Wales have provided a written statement and will give oral evidence to the Committee.  | Yes        |
| WHC/2022/001 | Not issued - last checked 29 September 2022                      |                                       |     |                |                    |  |   | Not Issued |
| WHC/2022/003 | Not issued - last checked 29 September 2022                      |                                       |     |                |                    |  |   | Not Issued |
| WHC/2022/004 | Not issued - last checked 29 September 2022                      |                                       |     |                |                    |  |   | Not Issued |

## WHC Received 1 January 2022 - 31 August 2022

| WHC Ref      | WHC Title  | Status             | Applicable to PHW? | Date Issued      | Deadline for Action /Response   | Lead Exec  | Compliance Statement  | Process Complete? |
|--------------|--|--------------------|--------------------|------------------|---------------------------------|--|---|-------------------|
| WHC/2022/006 | Direct Paramedic Referral to Same Day Emergency Care: All Wales Policy               | Action             | No                 | 21 April 2022    | Expires/Review 30 April 2026    | Not applicable to PHW  | Not applicable - WHC not applicable to PHW  | Not Applicable    |
| WHC/2022/007 | Recording of Dementia READ codes   | Action             | No                 | 15 February 2022 | 01 April 2022                   | Not applicable to PHW  | Not Applicable - WHC not applicable to PHW  | Not Applicable    |
| WHC/2022/009 | Prioritisation of COVID-19 patient episodes by NHS Wales Clinical Coding Departments | Compliance/Action  | No                 | 01 April 2022    | Expires/Review 28/02/2023       | Meng Khaw, National Director of Health Protection and Screening Services, Executive Medical Director | Not applicable - WHC not applicable to PHW  | Not Applicable    |
| WHC/2022/011 | Patient Testing Framework – Updated guidance   | Action             | No                 | 28 March 2022    | Review November 2022            | Not applicable to PHW  | Not applicable - WHC not applicable to PHW. Note: An updated version of this WHC was reissued in September.   | Not Applicable    |
| WHC/2022/012 | Donation and Transplantation Plan for Wales: 2022-2026                               | Action             | No                 | 16 June 2022     | Expires/Review 31 December 2026 |  | Not applicable - WHC not applicable to PHW  | Not Applicable    |
| WHC/2022/017 | Wales Rare Diseases Action Plan 2022 – 2026  | Action/Information | No                 | 16 June 2022     | Expires/Review 31 December 2026 | Meng Khaw, National Director of Health Protection and Screening Services, Executive Medical Director | <p>MK confirmed that there were no immediate actions for PHW, and referred to National Director Public Health Knowledge and Data (IB) to confirm any role for PHW in terms of raising awareness amongst health professionals through the work his team.</p> <p>IB confirmed PHW role within the Rare Disease Implementation Group (RDIG):</p> <p>CARIS team role:</p> <ul style="list-style-type: none"> <li>• Direct – collection of rare disease data. Childhood data collection is established. Adult data commenced during the pandemic (Gold approval) triggered by shielding. The long term data collection permissions and adequate resourcing of this new registry are a working progress – and both are included as milestones in the PHW IMTP.</li> <li>• Indirect – high level expert advice to RDIG (for example recent input to an evaluation metrics task and finish sub-committee.</li> <li>• Outputs – data summary outputs. The first academic publication was achieved approx. 2/52 ago (on Behcet's disease). Outputs will raise awareness amongst healthcare professionals (Priority 2).</li> <li>• Collaboration with other organisations in Wales – these collaborations should help prioritise future outputs and will also increase awareness of rare diseases amongst healthcare professionals (Priority 2), for example discussions around Cystic Fibrosis with respiratory clinicians based on the Llandough CF unit last week.</li> <li>• CARIS annual meeting – combination of showcasing congenital anomalies and rare diseases work – mainly to a healthcare professional/clinical audience – this is an established meeting that will support raising awareness amongst healthcare professionals (Priority 2). We are also involved in Priority 1 – 'Helping patients get a final diagnosis faster.' For example, we have been part of the recently established Syndrome Without A Name (SWAN) clinic evaluation discussions and CARIS will receive data from that clinic. In the future such data collection may help refine processes.</li> </ul> | Not Applicable    |
| WHC/2022/019 | Non Specialised Paediatric Orthopaedic Services                                      | Action             | No                 | 21 June 2022     | Expires/Review 1 April 2025     | Rhiannon Beaumont-Wood, Executive Director Quality, Nursing and Allied Health Professionals          | This WHC this is not applicable to PHW.   | Not Applicable    |